Cassie Bishop, NP
Family · Thomaston, GANPI 1932516309
Payments from drug & device makers
Across 113 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$372
- Lilly USA, LLC$319
- AbbVie$267
- Otsuka America Pharmaceutical, Inc.$204
- Astellas Pharma US Inc$148
- Bayer$112
- plus $748 from 20 others
What the payments were for
- Food & beverage$2,06795%
- Education$904%
- Entertainment$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $372 |
| Lilly USA, LLC | 18 | $319 |
| AbbVie | 19 | $267 |
| Otsuka America Pharmaceutical, Inc. | 8 | $204 |
| Astellas Pharma US Inc | 4 | $148 |
| Bayer | 6 | $112 |
| Mylan Specialty L.p. | 5 | $97 |
| Pfizer | 4 | $74 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $59 |
| Boehringer Ingelheim | 2 | $58 |
| Exact Sciences | 3 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Insulet Corporation | 1 | $47 |
| Johnson & Johnson | 2 | $43 |
| Azurity Pharmaceuticals, Inc. | 2 | $34 |
| GSK | 2 | $31 |
| Amgen | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $22 |
| Viiv Healthcare Company | 1 | $22 |
| AstraZeneca | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Medtronic | 1 | $18 |
| Linus Health, Inc. | 1 | $15 |
| Optos, Inc. | 1 | $14 |
How this compares
$2,172 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 28 | $46,165 |
| EliquisApixaban | 29 | $19,518 |
| OzempicSemaglutide | 20 | $18,956 |
| JardianceEmpagliflozin | 13 | $11,522 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,244 |
| FarxigaDapagliflozin Propanediol | 11 | $8,471 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 158 | $3,999 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,518 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,067 |
| Omeprazole | 95 | $929 |
| Gabapentin | 91 | $777 |
| Potassium Chloride | 24 | $651 |
| Atorvastatin Calcium | 97 | $648 |
| Amlodipine Besylate | 132 | $637 |
| Levothyroxine Sodium | 85 | $562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $319 | $46,16528 claims |
| PfizerEliquis | $74 | $19,51829 claims |
| Novo NordiskOzempic | $372 | $18,95620 claims |
| Boehringer IngelheimJardiance | $58 | $11,52213 claims |
| GSKTrelegy Ellipta | $31 | $9,24414 claims |
| AstraZenecaFarxiga | $20 | $8,47111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.
Other family in Thomaston
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.